John R. Mansueti M.D. | Find a Doctor

Dr. John R. Mansueti

Claim this profile

TidalHealth Richard A Henson Cancer Institute

Studies Prostate Cancer
Studies Prostate Adenocarcinoma
5 reported clinical trials
27 drugs studied

Affiliated Hospitals

Image of trial facility.

TidalHealth Richard A Henson Cancer Institute

Image of trial facility.

TidalHealth Peninsula Regional

Clinical Trials John R. Mansueti is currently running

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Hormone Therapy + Radiation

for Prostate Cancer

This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.

Recruiting

2 awards

Phase 3

1 criteria

More about John R. Mansueti

Clinical Trial Related

10 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments John R. Mansueti has experience with

  • Flutamide
  • Docetaxel
  • External Beam Radiation Therapy
  • Goserelin Acetate
  • Nilutamide
  • Intensity-Modulated Radiation Therapy (IMRT)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does John R. Mansueti specialize in?

Is John R. Mansueti currently recruiting for clinical trials?

Are there any treatments that John R. Mansueti has studied deeply?

What is the best way to schedule an appointment with John R. Mansueti?

What is the office address of John R. Mansueti?

Is there any support for travel costs?